|
Takeda Pharmaceutical Co. Ltd.
(NYSE: TAK)
|
9:00 PM UTC, 12/12/25 | |||
|---|---|---|---|---|
| Last: $14.33 | Change: -0.06 | %Change: -0.42% | Volume: 2,123,444 | |
04:40 AM EST, 01/21/2025 (MT Newswires) -- Takeda Pharmaceutical's (TAK) Takeda Canada said Monday that Health Canada has provided market authorization for Fruzaqla for the treatment of certain adult patients with metastatic colorectal cancer.
The authorization is based on data from two phase 3 trials in which Fruzaqla plus best supportive care showed "significant improvements in overall survival," with corresponding improvements in progression free survival, compared with placebo, the company said.
http://www.mtnewswires.com
Copyright © 2025 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.